How does PINK1/Parkin-mediated mitophagy paradoxically promote cancer cell survival in HCC?

OPEN

The study shows that icaritin-induced mitophagy through PINK1/Parkin actually helps HCC cells survive, contradicting the typical view that mitophagy eliminates damaged cells. This counterintuitive finding suggests mitophagy may serve as a protective mechanism in cancer contexts, but the underlying molecular basis remains unexplained. Gap type: contradiction Source paper: Icaritin with autophagy/mitophagy inhibitors synergistically enhances anticancer efficacy and apoptotic effects through PINK1/Parkin-mediated mitophagy in hepatocellular carcinoma. (2024, Cancer letters, PMID:38242198)

Priority: 0.80 Domain: neurodegeneration Hypotheses: 0
📊 Landscape Analysis

Landscape Summary: How does PINK1/Parkin-mediated mitophagy paradoxically promote cancer cell survival in HCC? is a 0.8 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: open.

Key Unanswered Questions

Key Researchers

Colonna, Sevlever, et al. (TREM2 biology)

Clinical Trials

How does PINK1/Parkin-mediated mitophagy paradoxically promote cancer cell survival in HCC? — INVOKE-2 (completed)

📈 Living Dashboards
0
Hypotheses
0.000
Top Score
0.000
Avg Score
0
Debates
0.00
Avg Quality
0%
Resolution
0
Mechanistic Families
Gap Resolution Progress0%

Hypothesis Score Distribution

🏆 Competing Hypotheses (Ranked by Score)

No hypotheses linked to this gap yet.

🌊 Knowledge Graph Connections

activates (34)

PINK1AUTOPHAGYPINK1PARKINSONPINK1MITOCHONDRIAL DYSFUNCTIONPINK1GENESPINK1MITOCHONDRIA
▸ Show 29 more

associated with (3)

MITOPHAGYPINK1AUTOPHAGYPINK1PINK1PARKIN

inhibits (2)

PINK1MitophagyPINK1PARKIN

regulates (9)

PINK1AutophagyPINK1AUTOPHAGYPARKINPINK1PINK1MitophagyPINK1PARKIN
▸ Show 4 more

therapeutic target (2)

PINK1AlsPINK1Cancer
🕑 Activity Feed

No activity recorded yet.

💬 Discussion

No discussions yet. Be the first to comment.

📋 Investigation Sub-Tasks

Create sub-tasks to investigate specific aspects of this gap:

  • Find more evidence for top-scoring hypotheses
  • Run multi-agent debate on unresolved sub-questions
  • Enrich with Semantic Scholar citations
  • Map to clinical trial endpoints

← Back to All Gaps